Garrido-Jareño, M. (Marta)

Filtering

2020 - 20212

Settings

Author search.filters.isAuthorOfPublication.0eb78f18-d2f0-412e-b098-99dcb5bdcfe4

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Estudio descriptivo de los casos de malaria en la población pediátrica en un hospital de referencia de Valencia, España, entre 1993 y 2015
    (2020) Ramírez-Cuentas, J.H. (John Helmut); Otero-Reigada, M.C. (Maria del Carmen); Garrido-Jareño, M. (Marta); Pemán-García, J. (Javier); Urtasun-Erburu, A. (Andrea); Roselló-Guijarro, M. (Mireia)
    Introduction: Malaria is considered to be the fourth leading cause of infant mortality after pneumonia, complications related to premature birth, and perinatal asphyxia. Material and methods: A retrospective and descriptive study of cases of malaria confirmed and treated by the Paediatric Infectious Diseases Unit (age lower than 15 years) at the La Fe Hospital, Valencia, over the period 1993 to 2015. Results: A total of 54 cases of paediatric malaria were diagnosed in the period 1993-2015, with 51.8% of these occurring in males, and 46.2% of patients were aged below 5 years. The majority of children came from Equatorial Guinea (68.5%). Only 5.6% had received antimalarial prophylaxis. Plasmodium falciparum was found to be the causal species in 81.4% of cases. Seven patients (13%) presented with complicated malaria. The most widely used treatment was quinine, either alone or in combination with other drugs. Atovaquone/proguanil was used from 2010 onwards and was indicated in 20.3% of the patients. The combination of artesunate/piperaquine/dihydroartemisinin began to be used in 2013. No deaths or relevant side effects were reported, and the clinical response was favourable in all children (100%). Conclusions: Malaria is still a prevalent disease in this population, a consequence of immigration, and tourism to endemic countries. Malaria should be considered as a likely diagnosis in a febrile child who comes from, or has travelled to, an endemic region in the past year.
  • Thumbnail Image
    A surface plasmon resonance based approach for measuring response to pneumococcal vaccine
    (2021) Garrido, J.M.; Pineda-Lucena, A. (Antonio); López-Hontangas, J.L. (José Luis); Orti-Pérez, L. (Leticia); Meyer-García, M.C. (María del Carmen); Lloret-Sos, C. (Carmina); Gil‑Brusola, A. (Ana); Garrido-Jareño, M. (Marta); Pemán-García, J. (Javier); Mollar‑Maseres, J. (Joan); Puchades-Carrasco, L. (Leonor); Sahuquillo-Arce, J.M. (José Miguel)
    Incidence of pneumococcal disease has increased worldwide in recent years. Response to pneumococcal vaccine is usually measured using the multiserotype enzyme-linked immunosorbent assay (ELISA) pneumococcal test. However, this approach presents several limitations. Therefore, the introduction of new and more robust analytical approaches able to provide information on the efficacy of the pneumococcal vaccine would be very beneficial for the clinical management of patients. Surface plasmon resonance (SPR) has been shown to offer a valuable understanding of vaccines' properties over the last years. The aim of this study is to evaluate the reliability of SPR for the anti-pneumococcal capsular polysaccharides (anti-PnPs) IgGs quantification in vaccinated. Fast protein liquid chromatography (FPLC) was used for the isolation of total IgGs from serum samples of vaccinated patients. Binding-SPR assays were performed to study the interaction between anti-PnPs IgGs and PCV13. A robust correlation was found between serum levels of anti-PnPs IgGs, measured by ELISA, and the SPR signal. Moreover, it was possible to correctly classify patients into "non-responder", "responder" and "high-responder" groups according to their specific SPR PCV13 response profiles. SPR technology provides a valuable tool for reliably characterize the interaction between anti-PnPs IgGs and PCV13 in a very short experimental time.